Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II

NCT06576427 · View on ClinicalTrials.gov ↗

Study Summary

This study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System in participants presenting with clinical signs and symptoms of acute pulmonary embolism.

Conditions Studied

Interventions

  • DEVICE Vertex Pulmonary Embolectomy System

Study Locations (20)

New York

  • NYU Langone Health — New York
  • Northwell Health — Staten Island
  • Westchester Medical Center — Valhalla

North Carolina

  • University of North Carolina — Chapel Hill
  • Duke University — Durham
  • Wake Forest Medical Center — Winston-Salem

Pennsylvania

  • Penn Presbyterian — Philadelphia
  • UPMC Presbyterian — Pittsburgh
  • St Clair Health — Pittsburgh

Michigan

  • Henry Ford Hospital — Detroit
  • Henry Ford St John — Detroit

Other

  • Medical University of Vienna — Vienna
  • St. John Paul II Hospital — Krakow

Connecticut

  • Hartford Hospital — Hartford

Florida

  • Ascension Sacred Heart — Pensacola

Georgia

  • Emory University — Atlanta

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2024-10-15
Est. Completion 2026-03
Phase NA

Sponsor

Jupiter Endovascular

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06576427

The ClinicalTrials.gov registry entry for NCT06576427 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jupiter Endovascular, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Pulmonary Embolism appearing as the primary indexed condition, and to 1 intervention — of which Vertex Pulmonary Embolectomy System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06576427 reports 20 study locations spanning 12 distinct geographic areas — top geographies include New York, North Carolina, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06576427 about?

NCT06576427 is a clinical study titled "Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II". This study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System in participants presenting with clinical signs and symptoms of acute pulmonary embolism.

What is the current status of trial NCT06576427?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 123 participants. The study started on 2024-10-15. Estimated completion is 2026-03.

What conditions does trial NCT06576427 study?

This clinical trial studies the following conditions: Pulmonary Embolism. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06576427?

The interventions under investigation include: Vertex Pulmonary Embolectomy System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06576427?

This trial is sponsored by Jupiter Endovascular, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06576427 being conducted?

This trial has 20 study locations across Connecticut, Florida, Georgia, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial